BidaskClub upgraded shares of OraSure Technologies (NASDAQ:OSUR) from a buy rating to a strong-buy rating in a research note issued to investors on Saturday.

Other equities analysts have also recently issued research reports about the stock. Zacks Investment Research raised shares of OraSure Technologies from a sell rating to a hold rating in a research note on Tuesday, January 9th. ValuEngine cut shares of OraSure Technologies from a buy rating to a hold rating in a research note on Thursday, November 2nd. Finally, Jefferies Group cut shares of OraSure Technologies from a buy rating to a hold rating in a research note on Thursday, November 2nd. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $19.65.

OraSure Technologies (NASDAQ OSUR) opened at $21.83 on Friday. The stock has a market cap of $1,320.00, a P/E ratio of 41.98, a PEG ratio of 4.87 and a beta of 1.27. OraSure Technologies has a 52 week low of $8.39 and a 52 week high of $23.01.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.09. The company had revenue of $42.30 million for the quarter, compared to analysts’ expectations of $40.87 million. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. The business’s revenue was up 31.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.11 EPS. research analysts predict that OraSure Technologies will post 0.43 earnings per share for the current year.

In other news, Director Mara G. Aspinall bought 5,000 shares of the firm’s stock in a transaction on Tuesday, November 7th. The stock was bought at an average cost of $14.23 per share, for a total transaction of $71,150.00. Following the completion of the acquisition, the director now directly owns 5,000 shares in the company, valued at approximately $71,150. The purchase was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 6.40% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. State Street Corp boosted its holdings in shares of OraSure Technologies by 6.9% in the second quarter. State Street Corp now owns 1,639,620 shares of the medical instruments supplier’s stock worth $28,305,000 after buying an additional 106,326 shares during the period. USA Financial Portformulas Corp boosted its holdings in shares of OraSure Technologies by 31.0% in the second quarter. USA Financial Portformulas Corp now owns 56,653 shares of the medical instruments supplier’s stock worth $978,000 after buying an additional 13,421 shares during the period. 361 Capital LLC boosted its holdings in shares of OraSure Technologies by 59.9% in the second quarter. 361 Capital LLC now owns 26,974 shares of the medical instruments supplier’s stock worth $466,000 after buying an additional 10,107 shares during the period. Voya Investment Management LLC boosted its holdings in shares of OraSure Technologies by 179.4% in the second quarter. Voya Investment Management LLC now owns 78,325 shares of the medical instruments supplier’s stock worth $1,352,000 after buying an additional 50,287 shares during the period. Finally, Macquarie Group Ltd. acquired a new position in shares of OraSure Technologies in the second quarter worth about $892,000. Institutional investors own 94.41% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://theolympiareport.com/2018/01/23/orasure-technologies-osur-stock-rating-upgraded-by-bidaskclub.html.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.